Neurocrine Biosciences, Inc.
NBIXNASDAQHealthcare● Active
$163.88
$-3.47(-2.07%)
Market Cap$16.5B
P/E Ratio—
52W High$168
52W Low$122.14
Neurocrine Biosciences, Inc. (NBIX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NBIX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$1.94
Est. $1.22 · +59.0%
Revenue
$0.81B
Est. $0.77B · +6.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
NBIX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.00
Rev. $0.01B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.00
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $2.11 | — | — | — | $0.87B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $1.22 | $1.94 | +59.0% | $0.81B | $0.77B | +6.0% |
| ▲ Q1 FY2026 | Feb 11, 2026 | $1.80 | $1.88 | +4.4% | $0.81B | $0.79B | +1.9% |
| ▲ Q4 FY2025 | Oct 28, 2025 | $1.58 | $2.04 | +29.1% | $0.79B | $0.81B | -1.5% |
| ▲ Q3 FY2025 | Jul 30, 2025 | $0.98 | $1.06 | +8.2% | $0.69B | $0.75B | -7.9% |
| ▼ Q2 FY2025 | May 5, 2025 | $0.54 | $0.08 | -85.0% | $0.57B | $0.56B | +2.3% |
| ▼ Q1 FY2025 | Feb 6, 2025 | $1.62 | $1.00 | -38.3% | $0.63B | $0.63B | -0.3% |
| ▼ Q4 FY2024 | Oct 30, 2024 | $1.51 | $1.24 | -17.9% | $0.62B | $0.60B | +3.6% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$2.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$1.94
EPS Est.
$1.22
EPS Surpr.
+59.0%
Revenue
$0.81B
Q1 FY2026
Feb 11, 2026Beat
EPS Actual
$1.88
EPS Est.
$1.80
EPS Surpr.
+4.4%
Revenue
$0.81B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
$2.04
EPS Est.
$1.58
EPS Surpr.
+29.1%
Revenue
$0.79B
Q3 FY2025
Jul 30, 2025Beat
EPS Actual
$1.06
EPS Est.
$0.98
EPS Surpr.
+8.2%
Revenue
$0.69B
Q2 FY2025
May 5, 2025Miss
EPS Actual
$0.08
EPS Est.
$0.54
EPS Surpr.
-85.0%
Revenue
$0.57B
Q1 FY2025
Feb 6, 2025Miss
EPS Actual
$1.00
EPS Est.
$1.62
EPS Surpr.
-38.3%
Revenue
$0.63B
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
$1.24
EPS Est.
$1.51
EPS Surpr.
-17.9%
Revenue
$0.62B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $5.16 | $5.93 | $6.44 | 7 |
| Q3 FY2028 | $5.00 | $5.74 | $6.23 | 4 |
| Q2 FY2028 | $4.87 | $5.59 | $6.07 | 6 |
| Q1 FY2028 | $4.52 | $5.20 | $5.64 | 4 |
| Q4 FY2027 | $2.83 | $3.25 | $3.52 | 6 |
| Q3 FY2027 | $2.74 | $3.14 | $3.41 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.4B | $1.6B | $1.7B | 8 |
| Q3 FY2028 | $1.4B | $1.6B | $1.7B | 6 |
| Q2 FY2028 | $1.4B | $1.5B | $1.6B | 5 |
| Q1 FY2028 | $1.3B | $1.5B | $1.6B | 5 |
| Q4 FY2027 | $1.1B | $1.2B | $1.3B | 6 |
| Q3 FY2027 | $1.1B | $1.2B | $1.3B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +59.0% | $134.07 | $135.06 | +0.74% |
| ▲ Q1 FY2026 | Feb 11, 2026 | +4.4% | $137.65 | $137.44 | -0.15% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +29.1% | $148.94 | $147.38 | -1.05% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +8.2% | $134.19 | $136.76 | +1.92% |
| ▼ Q2 FY2025 | May 5, 2025 | -85.0% | $109.68 | $109.75 | +0.06% |
| ▼ Q1 FY2025 | Feb 6, 2025 | -38.3% | $151.20 | $150.51 | -0.46% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -17.9% | $116.19 | $124.33 | +7.01% |
| ▼ Q3 FY2024 | Aug 1, 2024 | -40.0% | $141.57 | $153.15 | +8.18% |
Q2 FY2026+0.74%
Report Date
May 5, 2026
EPS Beat/Miss
+59.0%
Price Before
$134.07
Price After
$135.06
Q1 FY2026-0.15%
Report Date
Feb 11, 2026
EPS Beat/Miss
+4.4%
Price Before
$137.65
Price After
$137.44
Q4 FY2025-1.05%
Report Date
Oct 28, 2025
EPS Beat/Miss
+29.1%
Price Before
$148.94
Price After
$147.38
Q3 FY2025+1.92%
Report Date
Jul 30, 2025
EPS Beat/Miss
+8.2%
Price Before
$134.19
Price After
$136.76
Q2 FY2025+0.06%
Report Date
May 5, 2025
EPS Beat/Miss
-85.0%
Price Before
$109.68
Price After
$109.75
Q1 FY2025-0.46%
Report Date
Feb 6, 2025
EPS Beat/Miss
-38.3%
Price Before
$151.20
Price After
$150.51
Q4 FY2024+7.01%
Report Date
Oct 30, 2024
EPS Beat/Miss
-17.9%
Price Before
$116.19
Price After
$124.33
Q3 FY2024+8.18%
Report Date
Aug 1, 2024
EPS Beat/Miss
-40.0%
Price Before
$141.57
Price After
$153.15
Avg Beat Reaction+0.36%
Avg Miss Reaction+3.70%
Beat Rate4 / 8 quarters
Largest Move+8.18% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NBIX ends December
Neurocrine Biosciences, Inc. (NBIX) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $1.94 — beating the analyst consensus of $1.22 by +59.0%. NBIX has beaten EPS estimates for 4 consecutive quarters. The next NBIX earnings date is expected around September 1, 2026.
Each quarter, investors track NBIX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NBIX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NBIX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NBIX earnings · 5 questionsNeurocrine Biosciences, Inc.'s next earnings report is expected around September 1, 2026. NBIX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NBIX historically reports after market close (AMC).
NBIX earnings datewhen is NBIX earningsNBIX next earnings datewhen does NBIX report earningsNBIX earnings calendar
▸ Source: FMP · Neurocrine Biosciences, Inc. SEC filings · US GAAP · Neurocrine Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026